IRBP is producing RAVAX, a Phase III, potential first-in-class vaccine for the treatment of patients with early RA or with RA for less than 10 years. RAVAX is a vaccine that contains four 17-20mer (amino acids) (IR501) or 40mer (IR703) peptides against the T-cell receptor, specifically targetting autoreactive T cells, thus reducing their activity. The RAVAX vaccine is believed to target autoreactive T cells, while not affecting normal cells (IRBP, 2014b). Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.